Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga
Conditions
Interventions
Paxil CR
Locations
2
United States
GSK Investigational Site
Buffalo, New York, United States
GSK Investigational Site
Tacoma, Washington, United States
Start Date
July 7, 2008
Primary Completion Date
September 16, 2008
Completion Date
September 16, 2008
Last Updated
August 4, 2017
NCT07115329
NCT06793397
NCT07025720
NCT06780917
NCT04480918
NCT07422519
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions